Pfizer gets Phase II brain cancer vaccine from Celldex; later returns rights
Pfizer received exclusive worldwide rights from Avant's wholly owned Celldex Therapeutics division to a Phase II CDX110 vaccine for glioblastoma multiforme (GBM) and other cancer vaccines that target the epidermal growth factor receptor variant vIII (EGFRvIII).
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com